Trials / Active Not Recruiting

Active Not RecruitingNCT03414229

A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Phase II Study of Epacadostat (INCB024360) in Combination With Pembrolizumab in Patients With Locally Advanced/Metastatic Sarcoma

Status: Active Not Recruiting
Phase: Phase 2
Study type: Interventional
Enrollment: 30 (actual)

Sponsor: Memorial Sloan Kettering Cancer Center · Academic / Other
Sex: All
Age: 18 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to test any good and bad effects of the combination therapy of epacadostat and pembrolizumab and to determine how well the combination therapy works in the treatment of patients with sarcoma.

Conditions

Sarcoma

Interventions

Type	Name	Description
DRUG	Epacadostat	100mg bid days 1-21
DRUG	Pembrolizumab	200mg/dose Day 1, Q 3 weeks

Timeline

Start date: 2018-01-23
Primary completion: 2024-09-09
Completion: 2026-01-01
First posted: 2018-01-29
Last updated: 2025-05-02
Results posted: 2025-05-02

Locations

1 site across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT03414229. Inclusion in this directory is not an endorsement.